Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$159.9MBeat by $11.7M
EPS-$13.43Miss by $13.03
Revenue estimate$148.2M
EPS estimate-$0.40

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$178.1M
EPS estimate-$0.53

Financials

Q1 2026

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.57B+152%
Enterprise value$5.33B+162%
P/S9.8×+4.0×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%—

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Segments

By product

See full
Livmarli$113.8M+55.4%
Bile Acid Medicines$46.1M+20.1%

FAQ

When did Mirum Pharmaceuticals, Inc. report Q1 2026 earnings?
Mirum Pharmaceuticals, Inc. (MIRM) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Mirum Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Mirum Pharmaceuticals, Inc. reported revenue of $159.9M and eps of $-13.43 for Q1 2026.
Did Mirum Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $148.2M by $11.7M. EPS missed the consensus estimate of $-0.40 by $13.03.
How did Mirum Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 43.3% from $111.6M a year earlier and eps declined 4376.7% from $-0.30.
Where can I find Mirum Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-202609) and the 10-Q periodic report (0001759425-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.